REGN
Regeneron Pharmaceuticals, Inc.
- Depreciation and amortization, 2025
- $544M
- YoY, 2025
- +12.6%
- 5-year CAGR
- +18.2%
- 10-year CAGR
- +21.9%
Depreciation and amortization
Depreciation and amortization by fiscal year
| Period | D&A | YoY |
|---|---|---|
| 2025 | $544M | +12.6% |
| 2024 | $483M | +14.7% |
| 2023 | $421M | +23.3% |
| 2022 | $341M | +19.3% |
| 2021 | $286M | +21.3% |
| 2020 | $236M | +12.2% |
| 2019 | $210M | +41.9% |
| 2018 | $148M | +1.9% |
| 2017 | $146M | +39.0% |
| 2016 | $105M | +39.8% |
| 2015 | $75M | +42.2% |
| 2014 | $53M | +27.9% |
| 2013 | $41M | +11.5% |
| 2012 | $37M | +18.8% |
| 2011 | $31M | +57.9% |
| 2010 | $20M | +38.6% |
| 2009 | $14M | +25.8% |
| 2008 | $11M | — |